Related references
Note: Only part of the references are listed.Long-Acting Versus Standard Non-Ergot Dopamine Agonists in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials
Chang-Qing Zhou et al.
CNS NEUROSCIENCE & THERAPEUTICS (2014)
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients
Marios Politis et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
for the LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study (vol 13, pg 141, 2014)
C. W. Olen et al.
LANCET NEUROLOGY (2014)
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
Continuous subcutaneous infusion of apomorphine in Parkinson's disease: Retrospective analysis of a series of 81 patients
M. Rambour et al.
REVUE NEUROLOGIQUE (2014)
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
C. Warren Olanow et al.
LANCET NEUROLOGY (2014)
Non-dopaminergic Treatments for Motor Control in Parkinson's Disease
Susan H. Fox
DRUGS (2013)
Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
Peter A. LeWitt et al.
JOURNAL OF NEURAL TRANSMISSION (2013)
A phase 2, placebo-controlled, randomized, double-blind trial of tozadenant (Syn-115) in patients with Parkinson's disease with wearing-off fluctuations on levodopa
R.A. Hauser et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2013)
Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
Yoshikuni Mizuno et al.
MOVEMENT DISORDERS (2013)
AFQ056 in Parkinson Patients With Levodopa-Induced Dyskinesia: 13-Week, Randomized, Dose-Finding Study
Fabrizio Stocchi et al.
MOVEMENT DISORDERS (2013)
The Pharmacology of L-DOPA-Induced Dyskinesia in Parkinson's Disease
Philippe Huot et al.
PHARMACOLOGICAL REVIEWS (2013)
Levodopa-Induced Dyskinesia Is Strongly Associated with Resonant Cortical Oscillations
Par Halje et al.
JOURNAL OF NEUROSCIENCE (2012)
Perampanel, an AMPA antagonist, found to have no benefit in reducing off time in Parkinson's disease
Andrew Lees et al.
MOVEMENT DISORDERS (2012)
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
Peter A. LeWitt et al.
NEUROLOGY (2012)
Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial
O. Rascol et al.
PARKINSONISM & RELATED DISORDERS (2012)
Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications
Sophie Drapier et al.
PARKINSONISM & RELATED DISORDERS (2012)
Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: A prospective, open-label extension study
Lawrence W. Elmer et al.
PARKINSONISM & RELATED DISORDERS (2012)
A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation
Angelo Antonini et al.
JOURNAL OF NEUROLOGY (2011)
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2011)
Levetiracetam for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease
P. Stathis et al.
MOVEMENT DISORDERS (2011)
Botulinum Toxin Type A for Levodopa-Induced Cervical Dyskinesias in Parkinson's Disease: Unfavorable Risk-Benefit Ratio
Alberto J. Espay et al.
MOVEMENT DISORDERS (2011)
Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2011)
A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Dyskinesia in Parkinson's Disease
Kitty K. Wong et al.
MOVEMENT DISORDERS (2011)
PREPARED: Comparison of Prolonged and Immediate Release Ropinirole in Advanced Parkinson's Disease
Fabrizio Stocchi et al.
MOVEMENT DISORDERS (2011)
AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials
Daniela Berg et al.
MOVEMENT DISORDERS (2011)
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2011)
Extended-release pramipexole in advanced Parkinson disease A randomized controlled trial
A. H. V. Schapira et al.
NEUROLOGY (2011)
Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease The STRIDE-PD Study
Fabrizio Stocchi et al.
ANNALS OF NEUROLOGY (2010)
Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial
Martin Wolz et al.
JOURNAL OF NEURAL TRANSMISSION (2010)
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
Paolo Calabresi et al.
LANCET NEUROLOGY (2010)
Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease
Elisabeth Wolf et al.
MOVEMENT DISORDERS (2010)
Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
ARCHIVES OF NEUROLOGY (2009)
Levodopa-Induced Dyskinesias in Parkinson Disease Are Independent of the Extent of Striatal Dopaminergic Denervation: A Pharmacological and SPECT Study
Gurutz Linazasoro et al.
CLINICAL NEUROPHARMACOLOGY (2009)
Continuous dopaminergic stimulation by Duodopa® in advanced Parkinson's disease: Efficacy and safety
A. Annic et al.
REVUE NEUROLOGIQUE (2009)
Review: A review of the use of zonisamide in Parkinson’s disease
Pedro Emilio Bermejo et al.
Therapeutic Advances in Neurological Disorders (2009)
Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces Off' time in Parkinson's disease:: A double-blind, randomized, multicenter clinical trial (6002-US-005)
Peter A. LeWitt et al.
ANNALS OF NEUROLOGY (2008)
Combined 5-HTIA and 5-HTIB receptor agonists for the treatment of L-DOPA-induced dyskinesia
Ana Munoz et al.
BRAIN (2008)
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
M. Stacy et al.
NEUROLOGY (2008)
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
Robert A. Hauser et al.
MOVEMENT DISORDERS (2007)
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats
Manolo Carta et al.
BRAIN (2007)
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia
M. Angela Cenci
TRENDS IN NEUROSCIENCES (2007)
Advanced Parkinson disease treated with rotigotine transdermal system - PREFER Study
Peter A. LeWitt et al.
NEUROLOGY (2007)
Sarizotan as a treatment for dyskinesias in Parkinson's disease:: A double-blind placebo-controlled trial
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2007)
Zonisamide improves motor function in Parkinson disease - A randomized, double-blind study
Miho Murata et al.
NEUROLOGY (2007)
Post-versus presynaptic plasticity in L-DOPA-induced dyskinesia
M. Angela Cenci et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
C. Warren Olanow et al.
LANCET NEUROLOGY (2006)
Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia
KE Lyons et al.
CLINICAL NEUROPHARMACOLOGY (2006)
Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease
JN Caviness et al.
MOVEMENT DISORDERS (2006)
Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes
Galit Kleiner-Fisman et al.
MOVEMENT DISORDERS (2006)
Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs:: a prospective European study
M Péchevis et al.
EUROPEAN JOURNAL OF NEUROLOGY (2005)
Nondopaminergic mechanisms in levodopa-induced dyskinesia
JA Brotchie
MOVEMENT DISORDERS (2005)
Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning
C Guigoni et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2005)
Levodopa-dyskinesia incidence by age of Parkinson's disease onset
N Kumar et al.
MOVEMENT DISORDERS (2005)
Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years
MA Hely et al.
MOVEMENT DISORDERS (2005)
Clozapine improves dyskinesias in Parkinson disease - A double-blind, placebo-controlled study
F Durif et al.
NEUROLOGY (2004)
A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease
HL Tyne et al.
JOURNAL OF NEUROLOGY (2004)
Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease
S Paus et al.
MOVEMENT DISORDERS (2003)
Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease
F Stocchi et al.
BRAIN (2002)
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
I Shoulson et al.
ANNALS OF NEUROLOGY (2002)
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
JE Ahlskog et al.
MOVEMENT DISORDERS (2001)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
